#USA #New York #Kahn Swick #NV #uniQure

Background on the Case

uniQure N.V., a publicly traded biotech company, has come under fire following a significant delay in FDA approval for its promising drug candidate, AMT-130. This setback has not only affected the company's reputation but has also resulted in catastrophic losses for its investors. On October 31, 2025, the company’s shares were valued at $67.69, but just days later, on November 3, after disclosing the stark news from the FDA, the share price collapsed to $34.29, marking a staggering 49% drop. This decline prompted a class action lawsuit led by Kahn Swick & Foti, LLC, a law firm specializing in securities litigation.

Details of the Allegations

The lawsuit asserts that uniQure and its executives misled investors by apparently assuring them that AMT-130 was on track for accelerated approval from the FDA. Throughout the class period, from September 24 to October 31, 2025, uniQure maintained that it would file a Biologics License Application (BLA) based on their clinical trial data. However, the FDA's unexpected announcement indicated that the data submitted was insufficient, thus delaying the BLA submission process.

This misrepresentation and lack of transparency are at the core of the allegations against uniQure. By failing to disclose critical information, the executives are believed to have violated federal securities laws, which aims to protect investors from corporate malpractice.

Class Action Implications

Investors who suffered losses during the specified class period have until April 13, 2026, to file lead plaintiff applications. Led by Kahn Swick and Foti, the case is pending in the United States District Court for the Southern District of New York under the case name Scocco v. uniQure N.V. This is a pivotal opportunity for affected investors to recover their losses and hold the company accountable for its actions.

The lead plaintiff role is crucial as it helps shape the litigation's course and represents the interests of all investors in the class. To initiate claims, investors can contact KSF directly, emphasizing that the process incurs no obligation or fees upfront.

The Role of Kahn Swick & Foti, LLC

Kahn Swick & Foti is notable in the field of securities litigation, often representing both retail and institutional investors. Led by Lewis Kahn and partnered with former Louisiana Attorney General Charles C. Foti, Jr., the firm has established itself as a leading advocate for those affected by corporate fraud. KSF’s experience and robust track record in similar cases underscore their capability to navigate the complexities of such high-stakes litigation effectively.

The firm’s involvement reflects a growing trend of law firms taking action against biotech companies when investors face substantial losses due to misleading information. This case not only highlights the intricate world of biotech investments but also serves as a critical reminder to investors to remain vigilant about the accuracy of information provided by public companies.

Conclusion

As the class action against uniQure progresses, affected investors are urged to pay close attention to developments and to consider the opportunity to join the lawsuit. The timeline for participation is tight, but the potential for recovery may outweigh the risks. The outcome of the litigation could set a precedent for future cases involving biotech firms and their communications with investors. Investors must navigate these waters cautiously and seek legal counsel when necessary to protect their financial interests.

For those interested in learning more or actively participating in the class action, Kahn Swick & Foti provides avenues for engagement, detailed information about the lawsuit, and guidance on the next steps.